BioSpace News Archive

Virios Therapeutics announced Monday its lead asset IMC-1 fell short of its primary endpoint in the Phase IIb FORTRESS study in patients with fibromyalgia.

Both Bristol Myers Squibb and AbbVie filed a WARN notice with the California state government stating they intend to lay off up to 360 people.

The FDA approved bluebird bio’s lentiviral vector (LVV) eli-cel Friday as the first therapy to slow the progression of neurologic dysfunction in juvenile boys with early, active CALD.

Genfit announced that it is Versantis for roughly $40 million cash and approximately $65 million in milestone payments and other considerations.

The past week saw promising developments in candidate therapies for cancer, congenital hyperinsulinism, chronic cough and COVID-19 vaccines.

Research on Alzheimer’s, specifically in neuroscience, continues with the Alzheimer’s Drug Discovery Foundation, Critical Path Institute, Abbvie, AlzeCure Pharma and more.

Zentalis™ Pharmaceuticals, Inc. today announced the appointment of Carrie Brownstein, MD, as Chief Medical Officer (CMO), effective October 3, 2022.

Pfizer announced positive top-line results from its pivotal E.U. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate for the prevention of invasive pneumococcal disease, pneumonia, and acute otitis media caused by the 20 Streptococcus pneumoniae serotypes contained in the vaccine for the pediatric population.

H-CYTE, Inc. announced today that the Company has entered into a letter of intent to acquire SkinDisc, a patent pending tissue regeneration technology, that is expected to close within the next 30 days.

MiMedx Group, Inc. today announced the launch of AMNIOEFFECT™, a tri-layer PURION® processed human tissue allograft consisting of the amnion, intermediate, and chorion membrane layers of the placenta.